

Safety of bivalent omicron-containing mRNA-booster vaccines: a nationwide cohort study

Authors:

Niklas Worm Andersson, MD¹; Emilia Myrup Thiesson, MSc¹; Jørgen Vinsløv Hansen, MSc¹; Anders Hviid, DrMedSci^{1,2}

Affiliations:

¹ Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark

² Pharmacovigilance Research Center, Department of Drug Development and Clinical Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Corresponding author:

Niklas Worm Andersson, Department of Epidemiology Research, Statens Serum Institut, Copenhagen S 2300, Denmark, email: nian@ssi.dk, telephone: +45 3268 3159

Manuscript: word count (introduction through conclusion) 2275, 3 tables, and 2 figures

ABSTRACT

Background: Safety data to support bivalent omicron-containing mRNA-booster vaccination are lacking.

Methods: In a Danish nationwide cohort study from 1 January 2021 to 10 December 2022, we examined the association between bivalent omicron-containing mRNA-booster vaccination as a fourth Covid-19 vaccine dose and risk of adverse events in individuals aged ≥ 50 years. Using incidence rate ratios estimated with Poisson regression, we compared the rates of hospital visits for 27 different adverse events in a 28-day main risk period following vaccination with a bivalent omicron-containing mRNA-booster vaccine as a fourth dose to reference period rates from day 29 after the third or fourth vaccine dose and onward. Secondary analyses included stratifying by sex, age, and vaccine type and assessing the associations using self-controlled case series and observed vs. expected cohort analyses.

Results: 1,740,417 individuals (mean age 67.8 years, standard deviation 10.7) received a bivalent omicron-containing mRNA-booster vaccine as a fourth dose. Fourth dose vaccination with a bivalent omicron-containing booster did not statistically significantly increase the rate of any of the 27 adverse outcomes within 28 days, nor when analyzed according to age, sex, vaccine type, or using alternative analytical approaches. However, post-hoc analysis detected signals for myocarditis (statistically significantly so in females), although the outcome was very rare and findings were based on few cases. No risk of cerebrovascular infarction was found.

Conclusions: Bivalent omicron-containing mRNA-booster vaccination as a fourth dose was not associated with an increased risk of 27 different adverse events in 50+-year-olds.

INTRODUCTION

Bivalent mRNA-booster doses with either a Pfizer/BioNTech (original/omicron BA.4-5 or BA.1, *Comirnaty*) or a Moderna (original/omicron BA.1, *Spikevax*) vaccine that targets the original (ancestral) strain of SARS-CoV-2 and omicron subvariant BA.4-5 or BA.1 were authorized for use in early autumn 2022.¹⁻⁵ These bivalent omicron-containing mRNA-booster vaccines have subsequently been recommended as single boosters after the completion of a primary vaccination series, with or without a (original) monovalent first booster (i.e., a third vaccine dose).¹⁻⁵

In Denmark, rollout of the bivalent omicron-containing mRNA boosters started on 15 September 2022 and were recommended and offered to all individuals aged ≥ 50 years as well as to individuals considered at high risk of severe Covid-19. As the vaccine coverage of the third dose (i.e., first booster) has been high in Denmark ($>90\%$ for the targeted populations),⁶ the bivalent omicron-containing mRNA boosters have predominantly been administered as a fourth dose (i.e., second booster) to the general population aged ≥ 50 years.

Regulatory safety evaluations of the adapted bivalent mRNA-booster vaccines have primarily been based on available preauthorization clinical trials, post-marketing safety data of the monovalent mRNA vaccines, and clinical data on immunogenicity and reactogenicity of the bivalent mRNA vaccines.^{5,7-14} One recent report from the Centers of Disease Control and Prevention (CDC) of the early reported safety findings (mostly related to reactogenicity) through v-safe and the Vaccine Adverse Event Reporting System (VAERS) for the bivalent BA.4-5-containing boosters (i.e., as a ≥ 3 dose) appeared to be similar to those previously observed for monovalent vaccine boosters (not statistically analyzed).¹⁵ Consequently, data to adequately inform on the potential risk of adverse events associated with the bivalent mRNA vaccines are warranted.

In a nationwide cohort study, we investigated the association between the risk of 27 adverse events following vaccination with bivalent omicron-containing mRNA-booster vaccines as a fourth dose.

METHODS

Setting and study population

By use of the unique identifier assigned to all residents of Denmark upon birth or immigration, we linked data on Covid-19 vaccination, physician-assigned diagnoses, and other covariates from the nationwide healthcare registers, to construct a population-based cohort representative of the general Danish population potentially eligible for bivalent omicron-containing fourth dose booster vaccination during autumn 2022.^{16–19} As such, to be included in our cohort, an individual had to be born in 1972 or earlier (i.e. turning 50 years or older in 2022; age was defined as by 2022 minus birthyear), be a Danish resident at baseline 1 January 2021, and had to have received three prior vaccine doses with the monovalent BNT and/or MOD vaccines (or potentially AZD1222 vaccine (AstraZeneca) as part of primary vaccination)(see Table S1 in the Supplementary Appendix for details). We excluded individuals if they received the third dose within 90 days of the second dose (to ensure that the administered third dose was truly a first booster) or before 9 September 2021 (being the national rollout date of the first booster). We similarly censored fourth dose vaccinated if the vaccine was received before 15 September 2022 or within 90 days of the third dose. Vaccination status was classified in a time-varying manner during the period from 1 January 2021 to 10 December 2022. The main risk period of interest was within 28 days following the administration of the bivalent omicron-containing booster as a fourth dose while the reference period was from day 29 and after a third or fourth dose and onward (see Figure S1 for a graphical illustration of the study design).

According to Danish law, register-based research is exempt from ethics committee approval.

Outcomes

We included 27 different adverse events, adapted from prioritized lists of adverse events of special interest for the Covid-19 vaccines.^{20–22} During follow-up, we identified outcome events as any hospital visits where an outcome diagnosis was recorded as the primary reason for seeking hospital care (see Table S2 for

specific International Classification of Diseases, 10th revision-codes).¹⁶ We included only incident events by excluding individuals who had a history of the respective studied outcome during a washout period from 1 January 2018 to day 28 after the third dose. The date of admission served as the event date. Each of the 27 outcomes was studied separately.

Statistical analysis

Individuals were followed from day 29 after the third dose until first outcome event, emigration/disappearance, death, receipt of a fifth vaccine dose, or end of the study period. Individuals could contribute with person-time during both the main 28-day risk and the two reference periods; number of events and person-time from the two reference periods were aggregated. We used Poisson regression to estimate adjusted incidence rate ratios (IRRs), with corresponding 95% confidence intervals (CI), comparing the outcome rates during the risk period to the reference period rates. The model was adjusted for sex, age groups (50-64, 65-79, and ≥ 80 years), ethnicity (Nordic, Western, non-Western), region of residence, considered at high risk of severe Covid-19 (yes/no), calendar time (3-month-bins), and number of comorbidities (defined as asthma, other chronic respiratory disorders, chronic cardiac disorders, renal disorders, diabetes, autoimmune-related disorders, epilepsy, malignancies, and psychiatric disorders).

In secondary analysis, we analyzed the associations by sex, age, and the individual bivalent booster vaccine type, assessed the risk of severe outcome events, as defined by hospital contacts of ≥ 5 hours, including both primary and secondary the outcome definition, and altered the main risk period to 7, 14, and 90 days since fourth dose vaccination. Further, the robustness of the results from the primary analysis were evaluated by use of two alternative analytical approaches. First, nested within our study cohort, we conducted a self-controlled case series (SCCS) analysis;²³ in this design, only individuals experiencing an (incident) event were included, and we used conditional Poisson regression to estimate IRRs according to vaccination status. For the SCCS analysis, we excluded the 14 days prior to fourth dose vaccination from the reference period (to account for potential event-dependent exposure bias). An advantage of the SCCS

design is that time-periods are compared within study individuals which provides indirect adjustment of confounders not varying over the study period such as many lifestyle- and socioeconomic factor or comorbidities. Second, we compared the ratio between the observed rate of the studied outcome with the expected rate with 95% CIs obtained from the Poisson distribution. The expected rates were estimated using indirect age- and sex standardization of the historic background rates within the Danish general population from 1 January 2015 to 31 December 2019, emigration/disappearance.

In post-hoc analysis, we specifically addressed the risk of cerebrovascular infarction, myocarditis, and pericarditis separately, including in sex and age subgroups as well as for the individual bivalent booster vaccine types. We used SAS version 9.4 and R version 4.0.2 for data management, while statistical analysis was accomplished using R version 4.0.2.

RESULTS

Study population

The study cohort comprised a total of 2,225,567 individuals (mean age 66.9 years, standard deviation [SD] 11.0 years and 52.0% were females) who had received at least three Covid-19 vaccine doses (91.2% received a monovalent BNT vaccine as the third dose), of whom 1,740,417 (78.2%, mean age 68.7 years, SD 10.7 years) received a fourth dose with a bivalent omicron-containing mRNA-booster vaccine during 15 September 2022 to 10 December 2022 (Table 1). The bivalent BNT BA.4-5-containing booster was the most commonly administered (1,157,754 vaccine recipients, 66.5%), followed by the BNT and MOD BA.1-containing vaccines (526,397, 30.2% and 56,266, 3.3%, respectively). Except for chronic cardiac disorders (almost 10.0%), most comorbidities had a prevalence of $\leq 5.0\%$ within the cohort.

Risk of adverse events

Fourth dose vaccination with a bivalent omicron-containing mRNA-booster vaccine was not associated with a statistically significant increased rate of hospital visits for any of the 27 different adverse events within 28 days after vaccination as compared with the reference period rates (Figure 1). Similarly, no significant associations were found when stratifying by sex and age groups (Table 2) nor by the type of bivalent booster received (Figure 2 and Table S3). Using the alternative analytical approaches of SCCS (Table S4) and observed vs. expected (Table S5) analyses showed comparable results to our main analysis (except for a rate ratio of 2.22, 95% CI 1.27 to 3.60 for subacute thyroiditis based on 16 observed vs. 7.2 expected cases). Comparing the risk of severe adverse events, defined as hospital visits of ≥ 5 hours, showed close to similar results of the main analysis (Table S6; no cases of subacute thyroiditis requiring hospitalization for ≥ 5 hours were observed during the 28-day period following fourth dose vaccination). Including both primary and secondary diagnoses in the outcome definitions did not change the results (Table S7). Our secondary analysis with use of different risk periods of 7, 14, and 90 days following fourth dose vaccination showed an

increased risk of myocarditis or pericarditis (IRR 1.88, 95% CI 1.13 to 3.11) within 14 days only (Table S8); myocarditis and pericarditis were examined separately in post-hoc analyses.

Post-hoc analysis

No association between risk of cerebrovascular infarction and fourth dose bivalent booster vaccination was observed (IRR 0.95, 95% CI 0.87 to 1.05), including by sex, age, and type of bivalent booster (Table 3 and Table S9). We observed a total of 9 cases of myocarditis and 22 cases of pericarditis within 28 days following a fourth dose with a bivalent omicron-containing booster (equal to incidence rates of 5.3 and 13.0 cases within 28 days per 1,000,000 vaccinated, respectively; reference period incidence rates were 2.6 and 10.7 per 28 days among 1,000,000 individuals, respectively). The corresponding IRR was 2.65 (95% CI 1.01 to 6.97) for myocarditis and 1.21 (0.72 to 2.03) for pericarditis. Statistically significant associations with myocarditis were observed for females and the BNT BA.4-5-containing and MOD BA.1-containing boosters; the point estimate was similarly elevated for the BNT BA.1-containing booster but not statistically significant. Examining the associated risk of myocarditis with the individual vaccine types by sex and age groups showed statistically significant associations in females for all three vaccine types and in individuals aged 50 to 64 years who had been vaccinated with the MOD BA.1-containing booster (Table S9). However, all subgroup analyses of myocarditis risk were based on ≤ 6 cases among fourth dose vaccinated. No associations with pericarditis were found in any analysis.

DISCUSSION

In a nationwide cohort analysis, we evaluated the rate of 27 adverse events associated with the bivalent omicron-containing mRNA-booster vaccines received as the fourth dose in 1,740,417 individuals aged ≥ 50 years. We found no support for an increased risk of adverse events following vaccination with a bivalent omicron-containing mRNA booster as a fourth dose.

Our post-hoc analysis did reveal an excess of hospital visits due to myocarditis in females. However, myocarditis after bivalent omicron-containing mRNA-booster vaccination was a very rare event (a total of 9 cases) during the 28-day post-vaccination period of follow-up. In absolute numbers, we observed a rate of 5.3 cases in the 28-day post-vaccination period per 1,000,000 vaccinated, compared to a reference period incidence rate of 2.6 cases in 28-days per 1,000,000 individuals. Previous reported rates of myocarditis in adults following vaccination with the monovalent mRNA vaccines were highest in younger males.^{24–26} Five reports of myocarditis events following bivalent booster vaccination (not statistically analyzed) was received through VAERS in the recent CDC report on 22.6 million bivalent booster doses administered in the US to individuals aged ≥ 12 years.¹⁵

The CDC and the Food and Drug Administration (FDA) recently identified possible safety concerns of increased risk of cerebrovascular infarction following bivalent BNT BA.4-5-containing booster vaccination in adults aged ≥ 65 years due to detected preliminary safety signal by the CDC Vaccine Safety Datalink surveillance system.²⁷ We found no support for this notion, including no associations in any age, sex, and vaccine type subgroup analyses. Particularly, the upper 95% CI-bound from our analyses based on 1,157,754 fourth dose BNT BA.4-5-containing booster vaccinated individuals were inconsistent with relative increased risks of cerebrovascular infarction larger than 9% (IRR 0.97, 95% CI 0.86-1.09).

The robustness of the results from our main analysis is supported by SCCS analyses taking time invariant confounding into account and comparisons to historical rates. Furthermore, the use of nationwide demography- and health registers in a setting with universal access to free healthcare reduces concern

about selection- and information bias. However, a limitation of our study is that we cannot exclude differences in the ascertainment of adverse events between compared periods. The active comparative nature of our design, where we compare the 28-day period rates following fourth dose vaccination with reference periods rates from day 29 after vaccination, mitigates larger differences in outcome ascertainment as opposed to a comparison with unvaccinated period rates. However, ascertainment bias cannot be completely excluded; specifically, an increased awareness of any symptoms related to known adverse events (e.g., myocarditis) in the weeks following fourth dose vaccination relative to the reference periods with longer time since vaccination. However, this would bias the results towards increased risks in contrast to what we observe.

A strength of our study is the high statistical precision of many of the evaluated associations. For 19 of the 27 adverse events analyzed, the upper confidence interval bounds excluded 1.50 or higher, suggesting that moderate-to-large relative risk increases are unlikely.

Owing to the nationwide-based design, our findings have a high degree of generalizability to similar populations. In contrast, these results may only indirectly support safety evaluations of bivalent omicron-containing booster vaccination in other scenarios such as in individuals younger than 50 years old or other specific subgroups that were not studied.

CONCLUSION

Bivalent omicron-containing mRNA-booster vaccines administered as a fourth dose were not associated with an increased risk of 27 different adverse events in a general population of 50+-year-olds. These results provide reassuring support for the safety of bivalent booster vaccination, and provides critical and timely insight to patients, clinicians, and regulatory authorities.

ACKNOWLEDGMENT SECTION

Contributors: All authors conceptualized the study, interpreted the results and critically reviewed the manuscript; NA drafted the manuscript; NA, ET, and JH carried out the statistical analyses. AH supervised the study. NA had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analyses.

Funding: There was no specific funding for this study. No funder had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Declaration of interests: None.

Transparency: The lead author (the manuscript's guarantor) affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Ethics: The analyses were performed as surveillance activities analyses as part of the advisory tasks of the governmental institution Statens Serum Institut (SSI) for the Danish Ministry of Health. SSI's purpose is to monitor and fight the spread of disease in accordance with section 222 of the Danish Health Act. According to Danish law, national surveillance activities conducted by SSI do not require approval from an ethics committee. Both the Danish Governmental law firm and the compliance department of SSI have approved that the study is fully compliant with all legal, ethical, and IT-security requirements and there are no further approval procedures required for such studies.

Data sharing: No additional data available. Owing to data privacy regulations in Denmark, the raw data cannot be shared.

Dissemination to participants and related patient and public communities: Studied participants were anonymised in the utilised data sources; and therefore, direct dissemination to study participants is not possible. The study results will be disseminated to the public and health professionals by a press release written using layman's terms.

REFERENCES

1. FDA. Moderna COVID-19 Vaccines [Internet]. Food and Drug Administration. 2022 [cited 2023 Jan 5]; Available from: <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccines>
2. FDA. Pfizer-BioNTech COVID-19 Vaccines [Internet]. Food and Drug Administration. 2022 [cited 2023 Jan 5]; Available from: <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccines>
3. EMA. Spikevax (previously COVID-19 Vaccine Moderna) [Internet]. European Medicines Agency. 2021 [cited 2023 Jan 6]; Available from: <https://www.ema.europa.eu/en/medicines/human/EPAR/spikevax>
4. EMA. First adapted COVID-19 booster vaccines recommended for approval in the EU [Internet]. European Medicines Agency. 2022 [cited 2023 Jan 6]; Available from: <https://www.ema.europa.eu/en/news/first-adapted-covid-19-booster-vaccines-recommended-approval-eu>
5. EMA. Adapted vaccine targeting BA.4 and BA.5 Omicron variants original SARS-CoV-2 recommended for approval [Internet]. European Medicines Agency. 2022 [cited 2023 Jan 6]; Available from: <https://www.ema.europa.eu/en/news/adapted-vaccine-targeting-ba4-ba5-omicron-variants-original-sars-cov-2-recommended-approval>
6. Statens Serum Institut. Daglige opgørelser af tilslutningen til covid-19-vaccination [Internet]. [cited 2023 Jan 15]; Available from: <https://covid19.ssi.dk/overvagningsdata/arkiv---tidligere-overvaagningsdata/vaccinationstilslutning>

7. FDA. Pfizer-BioNTech COVID-19 Vaccine EUA LOA reissued December 8, 2022 [Internet]. Food and Drug Administration. 2022 [cited 2023 Jan 15];Available from:
<https://www.fda.gov/media/150386/download>
8. FDA. Moderna COVID-19 Vaccine EUA Letter of Authorization 12082022 [Internet]. Food and Drug Administration. 2022 [cited 2023 Jan 15];Available from:
<https://www.fda.gov/media/144636/download>
9. EMA. Spikevax (COVID-19 mRNA Vaccine (nucleoside modified)) [Internet]. European Medicines Agency. 2022 [cited 2023 Jan 15];Available from:
https://www.ema.europa.eu/en/documents/overview/spikevax-previously-covid-19-vaccine-moderna-epar-medicine-overview_en.pdf
10. Chalkias S, Harper C, Vrbicky K, et al. A Bivalent Omicron-Containing Booster Vaccine against Covid-19. *N Engl J Med* 2022;387(14):1279–91.
11. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 2020;383(27):2603–15.
12. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* 2021;384(5):403–16.
13. Chalkias S, Whatley J, Eder F, et al. Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19. *medRxiv* 2022;2022.12.11.22283166.
14. Klein NP, Lewis N, Goddard K, et al. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. *JAMA* 2021;326(14):1390–9.

15. Hause AM. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥ 12 Years — United States, August 31–October 23, 2022. *MMWR Morb Mortal Wkly Rep* [Internet] 2022 [cited 2022 Dec 15];71. Available from:
<https://www.cdc.gov/mmwr/volumes/71/wr/mm7144a3.htm>
16. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. *Scand J Public Health* 2011;39(7_suppl):30–3.
17. Schmidt M, Schmidt SAJ, Adelborg K, et al. The Danish health care system and epidemiological research: from health care contacts to database records. *Clin Epidemiol* 2019;11:563–91.
18. Pedersen CB. The Danish Civil Registration System. *Scand J Public Health* 2011;39(7_suppl):22–5.
19. Krause TG, Jakobsen S, Haarh M, Mølbak K. The Danish vaccination register. *Euro Surveill* 2012;17(17):20155.
20. BC-coordinator. Priority list of adverse events of special interest: COVID-19. 2020.
<https://brightoncollaboration.us/priority-list-aesicovid/>. Accessed October 15, 2021.
21. Center for Biologics Evaluation and Research Office of Biostatistics and Epidemiology. CBER Surveillance Program Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring Protocol. [Internet]. 2021 [cited 2021 Oct 10]; Available from:
<https://www.bestinitiative.org/wp-content/uploads/2021/02/C19-Vaccine-Safety-AESI-Background-Rate-Protocol-FINAL-2020.pdf>
22. Willame C, Dodd C, Durán C, et al. Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study. *Vaccine* [Internet] 2022 [cited 2022 Dec 2]; Available from:
<https://www.sciencedirect.com/science/article/pii/S0264410X22014293>

23. Farrington P, Whitaker H, Weldeselassie YG. Self-controlled case series studies: a modelling guide with R. Chapman and Hall/CRC; 2018.
24. Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. *N Engl J Med* 2021;385(23):2140–9.
25. Karlstad Ø, Hovi P, Husby A, et al. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. *JAMA Cardiology* 2022;7(6):600–12.
26. Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. *New England Journal of Medicine* 2021;385(23):2132–9.
27. CDC. COVID-19 Vaccination. CDC & FDA Identify Preliminary COVID-19 Vaccine Safety Signal for Persons Aged 65 Years and Older [Internet]. Centers for Disease Control and Prevention. 2020 [cited 2023 Jan 14]; Available from: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/bivalent-boosters.html>

FIGURE LEGENDS

Figure 1. Risk of adverse events within 28 days after vaccination with a bivalent omicron-containing mRNA-booster vaccine as the fourth dose in Danish 50+-year-olds during 15 September 2022 to 10 December 2022.

NE denotes not estimable.

Figure 2. Risk of adverse events within 28 days after vaccination with a bivalent omicron-containing mRNA-booster vaccine as the fourth dose in Danish 50+-year-olds during 15 September 2022 to 10 December 2022 by type of vaccine received.^a

BNT denotes BNT162b2, MOD mRNA-1273, and NE not estimable. ^aThe corresponding number of events and person-years are presented in Supplementary Table S3.

Table 1. Characteristics of all individuals vaccinated with a monovalent mRNA vaccine as a third dose and a bivalent omicron-containing vaccine as a fourth dose in Denmark.

	Third dose vaccinated	Bivalent booster fourth dose vaccinated
Characteristics		
Total vaccinated	2225567	1740417
Mean age (SD)	66.9 (11)	67.8 (10.7)
Female	1158395 (52.0%)	922067 (53.0%)
Ethnicity		
Nordic countries	2081076 (93.5%)	1655558 (95.1%)
Non-western countries	89347 (4.0%)	47037 (2.7%)
Western countries	55179 (2.5%)	37846 (2.2%)
Region of residency		
Northern Denmark Region	240019 (10.8%)	189601 (10.9%)
Central Denmark Region	503569 (22.6%)	398743 (22.9%)
Region of Southern Denmark	500917 (22.5%)	389586 (22.4%)
Capital Region of Denmark	622056 (28.0%)	482125 (27.7%)
Region Zealand	359006 (16.1%)	280362 (16.1%)
Vaccination priority groups		
High risk of severe Covid-19	107983 (4.9%)	72707 (4.2%)
Others	2117584 (95.1%)	1667710 (95.8%)
Vaccine received as the third dose		

	Third dose vaccinated	Bivalent booster fourth dose vaccinated
BNT	2029339 (91.2%)	1587589 (91.2%)
MOD	196228 (8.8%)	152828 (8.8%)
Vaccine received as the fourth dose		
Bivalent	1740417 (78.2%)	NA
Monovalent	53025 (2.4%)	NA
None	432125 (19.4%)	NA
Comorbidities		
Asthma	31236 (1.4%)	24998 (1.4%)
Chronic respiratory disorder	52497 (2.4%)	38581 (2.2%)
Chronic cardiac disorder	215737 (9.7%)	170772 (9.8%)
Renal disorder	21103 (0.9%)	13664 (0.8%)
Diabetes	80978 (3.6%)	62290 (3.6%)
Autoimmune-related disorder	112385 (5.0%)	84719 (4.9%)
Epilepsy	13933 (0.6%)	10723 (0.6%)
Malignancy	118556 (5.3%)	81375 (4.7%)
Psychiatric disorder	86531 (3.9%)	61330 (3.5%)

BNT denotes BNT162b2, MOD mRNA-1273, NA not applicable, and SD standard deviation. Values are numbers (percentages) unless otherwise stated. The bivalent fourth dose vaccinated stems from the entire three -dose vaccinated cohort. See Supplementary Table S1 for definitions and Figure S1 for an overview of the study design.

Table 2. Risk of adverse events within 28 days after vaccination with a bivalent omicron-containing mRNA-booster vaccine as the fourth dose in Danish 50+-year-olds during 15 September 2022 to 10 December 2022 by sex and age.

Outcome/subgroup	Number of events / person-years		Incidence rate ratio (95% CI)
	Bivalent boosters	Reference period	
Anaphylaxis			
Female	14 / 68995	186 / 990447	0.82 (0.44-1.52)
Male	16 / 61165	177 / 901198	1.27 (0.69-2.34)
Aged 50 to 64 years	11 / 53473	140 / 865609	1.03 (0.51-2.07)
Aged 65 to 79 years	14 / 56826	164 / 746874	0.95 (0.50-1.81)
Aged 80 years or older	5 / 19860	59 / 279162	1.20 (0.40-3.59)
Ischemic cardiac event			
Female	231 / 67655	3327 / 972545	0.93 (0.79-1.08)
Male	441 / 58541	6665 / 865900	0.96 (0.86-1.08)
Aged 50 to 64 years	169 / 52502	3089 / 850978	0.89 (0.75-1.06)
Aged 65 to 79 years	373 / 54742	4821 / 720529	1.04 (0.91-1.18)
Aged 80 years or older	130 / 18953	2082 / 266938	0.82 (0.67-1.01)
Cerebrovascular event			
Female	365 / 67597	5229 / 971701	0.93 (0.82-1.05)
Male	433 / 59288	6294 / 876030	1.00 (0.89-1.12)
Aged 50 to 64 years	132 / 52883	2276 / 856918	0.90 (0.74-1.10)

Outcome/subgroup	Number of events / person-years		Incidence rate ratio (95% CI)
	Bivalent boosters	Reference period	
Aged 65 to 79 years	385 / 55219	5200 / 726358	0.96 (0.85-1.09)
Aged 80 years or older	281 / 18783	4047 / 264456	1.01 (0.87-1.16)
Arterial thromboembolism			
Female	10 / 69028	187 / 990873	0.79 (0.38-1.64)
Male	11 / 61174	198 / 901261	1.18 (0.57-2.46)
Aged 50 to 64 years	3 / 53502	88 / 866028	0.84 (0.23-3.09)
Aged 65 to 79 years	12 / 56846	179 / 747045	0.91 (0.46-1.81)
Aged 80 years or older	6 / 19854	118 / 279061	1.08 (0.41-2.82)
Deep vein thrombosis			
Female	111 / 68480	1621 / 983407	0.98 (0.79-1.23)
Male	126 / 60508	1972 / 892241	0.94 (0.76-1.16)
Aged 50 to 64 years	80 / 53134	1170 / 860542	1.11 (0.86-1.45)
Aged 65 to 79 years	113 / 56290	1552 / 739945	0.94 (0.75-1.17)
Aged 80 years or older	44 / 19564	871 / 275162	0.81 (0.57-1.14)
Pulmonary embolism			
Female	107 / 68630	1625 / 985567	0.84 (0.67-1.06)
Male	109 / 60748	1711 / 895550	0.84 (0.68-1.05)
Aged 50 to 64 years	36 / 53326	759 / 863542	0.72 (0.49-1.03)
Aged 65 to 79 years	110 / 56446	1579 / 741886	0.81 (0.65-1.02)

Outcome/subgroup	Number of events / person-years		Incidence rate ratio (95% CI)
	Bivalent boosters	Reference period	
Aged 80 years or older	70 / 19606	998 / 275689	0.98 (0.73-1.29)
Myocarditis or pericarditis			
Female	15 / 69029	130 / 990933	1.40 (0.73-2.68)
Male	14 / 61168	192 / 901182	1.28 (0.67-2.46)
Aged 50 to 64 years	11 / 53482	159 / 865748	1.28 (0.62-2.64)
Aged 65 to 79 years	16 / 56848	122 / 747120	1.45 (0.75-2.78)
Aged 80 years or older	2 / 19867	41 / 279247	0.83 (0.16-4.22)
Cerebral venous thrombosis			
Female	1 / 69067	20 / 991453	1.08 (0.10-11.69)
Male	2 / 61229	17 / 902057	2.09 (0.30-14.53)
Aged 50 to 64 years	1 / 53523	16 / 866393	2.67 (0.17-41.78)
Aged 65 to 79 years	2 / 56892	18 / 747686	1.23 (0.21-7.28)
Aged 80 years or older	0 / 19881	3 / 279431	NE
Thrombocytopenia or coagulative disorder			
Female	16 / 68972	234 / 990059	0.88 (0.49-1.58)
Male	14 / 61130	255 / 900620	0.63 (0.35-1.14)
Aged 50 to 64 years	10 / 53452	163 / 865273	0.80 (0.39-1.63)
Aged 65 to 79 years	14 / 56811	200 / 746567	0.71 (0.38-1.31)
Aged 80 years or older	6 / 19840	126 / 278839	0.74 (0.29-1.88)

Outcome/subgroup	Number of events / person-years		Incidence rate ratio (95% CI)
	Bivalent boosters	Reference period	
Guillain-Barré syndrome			
Female	0 / 69066	22 / 991431	NE
Male	1 / 61225	26 / 901994	0.53 (0.06-4.65)
Aged 50 to 64 years	1 / 53522	19 / 866363	0.54 (0.06-4.63)
Aged 65 to 79 years	0 / 56890	18 / 747639	NE
Aged 80 years or older	0 / 19880	11 / 279424	NE
Bell's palsy			
Female	15 / 69003	224 / 990574	0.92 (0.50-1.67)
Male	14 / 61160	225 / 901105	1.04 (0.55-1.96)
Aged 50 to 64 years	11 / 53465	222 / 865526	0.73 (0.38-1.43)
Aged 65 to 79 years	11 / 56835	168 / 746966	1.11 (0.53-2.34)
Aged 80 years or older	7 / 19863	59 / 279187	1.68 (0.63-4.48)
Transverse myelitis			
Female	0 / 69070	9 / 991491	NE
Male	0 / 61234	4 / 902106	NE
Aged 50 to 64 years	0 / 53526	7 / 866417	NE
Aged 65 to 79 years	0 / 56896	4 / 747729	NE
Aged 80 years or older	0 / 19882	2 / 279451	NE
Encephalomyelitis or encephalitis			

Outcome/subgroup	Number of events / person-years		Incidence rate ratio (95% CI)
	Bivalent boosters	Reference period	
Female	6 / 69061	29 / 991347	2.54 (0.78-8.26)
Male	3 / 61221	38 / 901930	0.83 (0.22-3.13)
Aged 50 to 64 years	4 / 53518	32 / 866291	1.72 (0.49-6.07)
Aged 65 to 79 years	4 / 56885	25 / 747576	1.86 (0.47-7.40)
Aged 80 years or older	1 / 19879	10 / 279410	0.63 (0.07-5.94)
Narcolepsy			
Female	0 / 69066	5 / 991426	NE
Male	0 / 61230	2 / 902058	NE
Aged 50 to 64 years	0 / 53521	5 / 866351	NE
Aged 65 to 79 years	0 / 56893	2 / 747695	NE
Appendicitis			
Female	71 / 68714	1067 / 986842	0.92 (0.70-1.21)
Male	55 / 60961	844 / 898443	1.15 (0.83-1.60)
Aged 50 to 64 years	46 / 53257	870 / 862454	0.95 (0.68-1.33)
Aged 65 to 79 years	56 / 56623	766 / 744469	1.01 (0.73-1.40)
Aged 80 years or older	24 / 19795	275 / 278362	1.13 (0.69-1.85)
Aseptic arthritis			
Female	86 / 68542	1169 / 984199	0.85 (0.66-1.10)
Male	129 / 60312	2044 / 889449	0.90 (0.73-1.10)

Outcome/subgroup	Number of events / person-years		Incidence rate ratio (95% CI)
	Bivalent boosters	Reference period	
Aged 50 to 64 years	64 / 53104	1074 / 859993	0.89 (0.67-1.18)
Aged 65 to 79 years	95 / 56207	1381 / 738857	0.84 (0.66-1.07)
Aged 80 years or older	56 / 19544	758 / 274798	0.95 (0.69-1.30)
Type 1 diabetes mellitus			
Female	6 / 68604	221 / 985032	0.48 (0.20-1.16)
Male	18 / 60637	338 / 893587	0.97 (0.56-1.69)
Aged 50 to 64 years	13 / 53018	268 / 859010	0.79 (0.42-1.47)
Aged 65 to 79 years	6 / 56448	225 / 741687	0.64 (0.25-1.61)
Aged 80 years or older	5 / 19775	66 / 277921	1.23 (0.41-3.69)
Subacute thyroiditis			
Female	8 / 69043	90 / 991095	1.98 (0.77-5.08)
Male	8 / 61222	48 / 901951	1.39 (0.57-3.34)
Aged 50 to 64 years	4 / 53500	87 / 866015	0.86 (0.28-2.65)
Aged 65 to 79 years	11 / 56886	42 / 747609	2.07 (0.88-4.84)
Aged 80 years or older	1 / 19880	9 / 279422	7.50 (0.26-214.14)
Heart failure			
Female	193 / 68101	3274 / 978071	0.78 (0.66-0.92)
Male	320 / 59476	5135 / 877652	0.79 (0.70-0.90)
Aged 50 to 64 years	83 / 53055	1376 / 859389	0.91 (0.71-1.16)

Outcome/subgroup	Number of events / person-years		Incidence rate ratio (95% CI)
	Bivalent boosters	Reference period	
Aged 65 to 79 years	230 / 55598	3613 / 730468	0.75 (0.64-0.87)
Aged 80 years or older	200 / 18925	3420 / 265866	0.78 (0.67-0.92)
Arrythmia			
Female	655 / 65096	9247 / 938393	0.92 (0.84-1.01)
Male	875 / 55862	12395 / 830931	0.93 (0.86-1.01)
Aged 50 to 64 years	274 / 52072	4362 / 845493	0.97 (0.85-1.12)
Aged 65 to 79 years	791 / 52230	10470 / 688849	0.93 (0.85-1.01)
Aged 80 years or older	465 / 16656	6810 / 234982	0.90 (0.81-1.01)
Acute liver failure			
Female	5 / 69028	171 / 990873	0.44 (0.17-1.14)
Male	5 / 61196	204 / 901549	0.35 (0.14-0.90)
Aged 50 to 64 years	3 / 53500	132 / 865997	0.36 (0.11-1.19)
Aged 65 to 79 years	3 / 56856	182 / 747160	0.23 (0.07-0.75)
Aged 80 years or older	4 / 19869	61 / 279265	0.97 (0.30-3.13)
Acute kidney failure			
Female	116 / 68599	1750 / 984823	0.83 (0.67-1.03)
Male	120 / 60652	2069 / 893719	0.73 (0.60-0.90)
Aged 50 to 64 years	47 / 53306	729 / 862895	0.93 (0.66-1.29)
Aged 65 to 79 years	113 / 56377	1763 / 740653	0.73 (0.59-0.91)

Outcome/subgroup	Number of events / person-years		Incidence rate ratio (95% CI)
	Bivalent boosters	Reference period	
Aged 80 years or older	76 / 19568	1327 / 274994	0.77 (0.59-1.00)
Acute pancreatitis			
Female	38 / 68902	593 / 989234	0.85 (0.59-1.24)
Male	39 / 61047	663 / 899594	0.79 (0.55-1.14)
Aged 50 to 64 years	16 / 53409	415 / 864657	0.53 (0.31-0.91)
Aged 65 to 79 years	35 / 56734	521 / 745705	0.77 (0.52-1.14)
Aged 80 years or older	26 / 19806	320 / 278466	1.46 (0.89-2.39)
Erythema multiforme			
Female	0 / 69068	22 / 991455	NE
Male	1 / 61231	14 / 902073	1.01 (0.09-10.88)
Aged 50 to 64 years	0 / 53525	8 / 866412	NE
Aged 65 to 79 years	1 / 56893	17 / 747691	0.88 (0.08-9.42)
Aged 80 years or older	0 / 19880	11 / 279425	NE
Seizure			
Female	47 / 68603	805 / 984905	0.84 (0.60-1.18)
Male	64 / 60713	983 / 894747	0.85 (0.64-1.14)
Aged 50 to 64 years	24 / 53162	583 / 860954	0.63 (0.40-0.98)
Aged 65 to 79 years	67 / 56457	833 / 741864	1.08 (0.80-1.46)
Aged 80 years or older	20 / 19698	372 / 276834	0.65 (0.39-1.07)

Outcome/subgroup	Number of events / person-years		Incidence rate ratio (95% CI)
	Bivalent boosters	Reference period	
Arterial aneurysm			
Female	76 / 68683	1005 / 986383	0.85 (0.65-1.10)
Male	222 / 60146	2561 / 887920	1.04 (0.89-1.23)
Aged 50 to 64 years	70 / 53285	759 / 863051	1.26 (0.95-1.68)
Aged 65 to 79 years	158 / 56066	1972 / 737299	0.86 (0.72-1.04)
Aged 80 years or older	70 / 19477	835 / 273952	1.08 (0.81-1.44)
Uveitis			
Female	19 / 68942	340 / 989707	1.10 (0.64-1.91)
Male	12 / 61136	282 / 900711	0.69 (0.36-1.32)
Aged 50 to 64 years	11 / 53432	272 / 864929	0.86 (0.43-1.69)
Aged 65 to 79 years	12 / 56798	249 / 746478	0.76 (0.39-1.49)
Aged 80 years or older	8 / 19848	101 / 279011	1.23 (0.52-2.93)

NE denotes not estimable.

Table 3. Risk of cerebrovascular infarction, myocarditis, and pericarditis following fourth dose vaccination with a bivalent omicron-containing booster within 28 days in Danish 50+-year-olds during 15 September 2022 to 10 December 2022 including by sex, age, and vaccine type.


Outcome/subgroup	Bivalent boosters		Reference period		Incidence rate ratio (95% CI)
	Events/ person-years	Rate/ 1,000,000 ^a	Events/ person- years	Rate/ 1,000,000 ^a	
Cerebrovascular infarction (including TIA)					
All	644 / 127304	387.8	9687 / 1853451	400.7	0.95 (0.87-1.05)
Females	290 / 67794	327.9	4317 / 974392	339.6	0.91 (0.79-1.05)
Males	354 / 59511	456.0	5370 / 879059	468.3	0.99 (0.88-1.13)
Aged 50 to 64 years	113 / 52983	163.5	1910 / 858398	170.6	0.96 (0.78-1.20)
Aged 65 to 79 years	315 / 55419	435.7	4426 / 728948	465.5	0.94 (0.82-1.07)
Aged 80 years or older	216 / 18902	876.0	3351 / 266105	965.4	0.98 (0.83-1.15)
BNT BA.4-5-containing	377 / 84259	343.0	9687 / 1853451	400.7	0.97 (0.86-1.09)
BNT BA.1-containing	246 / 38856	485.3	9687 / 1853451	400.7	0.98 (0.85-1.12)
MOD BA.1-containing	21 / 4189	384.3	9687 / 1853451	400.7	0.83 (0.54-1.29)
Myocarditis					
All	9 / 130288	5.3	64 / 1893405	2.6	2.65 (1.01-6.97)
Females	6 / 69066	6.7	29 / 991433	2.2	3.89 (1.05-14.50)
Males	3 / 61223	3.8	35 / 901972	3.0	1.60 (0.36-7.07)
Aged 50 to 64 years	4 / 53520	5.7	30 / 866339	2.7	3.29 (0.75-14.46)

Outcome/subgroup	Bivalent boosters		Reference period		Incidence rate ratio (95% CI)
	Events/ person-years	Rate/ 1,000,000 ^a	Events/ person- years	Rate/ 1,000,000 ^a	
Aged 65 to 79 years	4 / 56889	5.4	27 / 747644	2.8	1.79 (0.45-7.08)
Aged 80 years or older	1 / 19880	3.9	7 / 279421	1.9	10.13 (0.23-437.19)
BNT BA.4-5-containing	6 / 85859	5.4	64 / 1893405	2.6	3.74 (1.16-12.05)
BNT BA.1-containing	2 / 40146	3.8	64 / 1893405	2.6	2.59 (0.52-12.94)
MOD BA.1-containing	1 / 4283	17.9	64 / 1893405	2.6	12.39 (1.46-105.47)
Pericarditis					
All	22 / 130215	13.0	265 / 1892351	10.7	1.21 (0.72-2.03)
Females	11 / 69036	12.2	104 / 991018	8.0	1.20 (0.57-2.50)
Males	11 / 61179	13.8	161 / 901332	13.7	1.22 (0.59-2.53)
Aged 50 to 64 years	8 / 53490	11.5	134 / 865857	11.9	1.09 (0.48-2.48)
Aged 65 to 79 years	13 / 56856	17.5	96 / 747218	9.8	1.47 (0.71-3.05)
Aged 80 years or older	1 / 19869	3.9	35 / 279276	9.6	0.43 (0.05-3.67)
BNT BA.4-5-containing	14 / 85811	12.5	265 / 1892351	10.7	0.85 (0.43-1.71)
BNT BA.1-containing	7 / 40123	13.4	265 / 1892351	10.7	1.12 (0.48-2.64)
MOD BA.1-containing	1 / 4281	17.9	265 / 1892351	10.7	1.82 (0.25-13.31)

BNT denotes BNT162b2, MOD mRNA-1273, NE not estimable, and TIA transient cerebral ischemic attack. ^aRate/1,000,000 is the incidence rate per 1,000,000 vaccinated (or individuals for reference period) within 28 days. Sex and age subgroup estimates for the individual bivalent omicron-containing mRNA-booster vaccine types are presented in Supplementary Table S8.

Number of events / person-years

Outcome	Bivalent boosters	Reference period	IRR (95% CI)	Incidence rate ratio (95% CI)
Anaphylaxis	30 / 130159	363 / 1891645	1.01 (0.66–1.56)	
Ischemic cardiac event	672 / 126196	9992 / 1838445	0.95 (0.87–1.04)	
Cerebrovascular event	798 / 126885	11523 / 1847732	0.97 (0.89–1.05)	
Arterial thromboembolism	21 / 130201	385 / 1892134	0.96 (0.57–1.60)	
Deep vein thrombosis	237 / 128988	3593 / 1875648	0.96 (0.82–1.12)	
Pulmonary embolism	216 / 129377	3336 / 1881117	0.84 (0.72–0.99)	
Myocarditis or pericarditis	29 / 130197	322 / 1892114	1.34 (0.85–2.13)	
Cerebral venous thrombosis	3 / 130296	37 / 1893510	1.60 (0.36–7.04)	
Thrombocytopenia and coagulative disorders	30 / 130103	489 / 1890679	0.75 (0.49–1.13)	
Guillain–Barré syndrome	1 / 130291	48 / 1893425	0.19 (0.03–1.50)	
Bell's palsy	29 / 130163	449 / 1891679	0.97 (0.63–1.50)	
Transverse myelitis	0 / 130304	13 / 1893597	NE	
Encephalomyelitis or encephalitis	9 / 130282	67 / 1893277	1.50 (0.64–3.50)	
Narcolepsy	0 / 130296	7 / 1893484	NE	
Appendicitis	126 / 129675	1911 / 1885284	1.01 (0.82–1.25)	
Aseptic arthritis	215 / 128854	3213 / 1873649	0.88 (0.75–1.03)	
Type 1 diabetes mellitus	24 / 129241	559 / 1878619	0.77 (0.49–1.23)	
Subacute thyroiditis	16 / 130265	138 / 1893046	1.64 (0.87–3.12)	
Heart failure	513 / 127578	8409 / 1855724	0.79 (0.71–0.87)	
Arrythmia	1530 / 120958	21642 / 1769324	0.93 (0.87–0.98)	
Acute liver failure	10 / 130224	375 / 1892422	0.39 (0.20–0.76)	
Acute kidney failure	236 / 129251	3819 / 1878542	0.78 (0.67–0.91)	
Acute pancreatitis	77 / 129949	1256 / 1888828	0.82 (0.63–1.07)	
Erythema multiforme	1 / 130298	36 / 1893528	0.40 (0.05–3.37)	
Seizure	111 / 129316	1788 / 1879652	0.85 (0.68–1.06)	
Arterial aneurysm	298 / 128829	3566 / 1874303	0.99 (0.86–1.13)	
Uveitis	31 / 130078	622 / 1890418	0.89 (0.59–1.36)	



Bivalent boosters vs reference period, IRR (95% CI)

